Center for Molecular Analysis of Disease Pathways (CMADP)

An NIH Center of Biomedical Research Excellence (COBRE)

The development of new enabling technologies is critical to improving our understanding and treatment of disease. The Center for Molecular Analysis of Disease Pathways (CMADP), an NIH Center for Biomedical Research Excellence (COBRE), brings together junior and senior faculty from the physical, biological, and pharmaceutical sciences at the University of Kansas and other academic institutions in Kansas to conduct multidisciplinary research to develop and implement cutting-edge technologies for elucidating the genetic, chemical, and physical mechanisms of biological processes involved in disease.

MRB Photo

Microfabrication & Microfluidics Core

The scientific emphasis of the Center is on the creation and implementation of enabling technologies that can be employed to identify new therapeutic targets. This includes state of the art methods for gene sequencing, the genetic manipulation of model organisms, custom fluorescent molecular probes for monitoring physiological processes in model organisms, and microfluidic systems for manipulation and monitoring of biochemical pathways.

CMADP capitalizes on existing and evolving expertise in the fields of bioanalytical chemistry, molecular design, genomics and bioengineering at the University of Kansas (KU) and Kansas State University (KSU). The PI, Co-Investigators, research investigators, core directors, mentors, and members of the internal advisory committee represent ten academic departments, six Colleges and Schools, and two Research Centers at KU and KSU. The departments of Biology and Chemistry at KSU are also represented by members of the CMADP's core facility steering committees. The senior faculty members in these departments, schools and centers have a long history of research collaborations and cross-training of graduate students and post-doctoral associates.

Research reported in this Web site was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103638. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Recent News

February 2017
CMADP Project Investigators co-author Top Downloaded article in Lab on a Chip

CMADP Co-I awarded R01 from NIH National Cancer Institute

CMADP Graduate's research featured on cover of Genetics and in other journals

October 2016
CMADP Co-I receives Mathers Foundation grant

View all news »

Upcoming Events
Special seminar by Dr. Kevin W. Plaxco
Professor of Chemistry & Biochemistry
UC Santa Barbara

Wednesday, April 19, 2017 at 4:00pm
School of Pharmacy, Room 3020

"Counting molecules, dodging blood cells: real-time molecular measurements directly in the living body"
The development of technology capable of continuously tracking the levels of drugs, metabolites, and biomarkers in situ in the body would revolutionize our understanding of health and our ability to detect and treat disease. It would, for example, provide clinicians with a real-time window into organ function and would enable therapies guided by patient-specific, real-time pharmacokinetics, opening a new dimension in personalized medicine. In response my group has pioneered the development of a “biology-inspired” electrochemical approach to monitoring specific molecules that supports real-time measurements of arbitrary molecular targets (irrespective of their chemical reactivity) directly in awake, fully ambulatory subjects.
KU Today